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The development of immune checkpoint inhibitors represents a major breakthrough in cancer
therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway
blockade. Evidence for WNT/β-catenin signaling-mediated immune evasion is found in a
subset of cancers including melanoma. Currently, there are no therapeutic strategies avail-
able for targeting WNT/β-catenin signaling. Here we show that a specific small-molecule
tankyrase inhibitor, G007-LK, decreases WNT/β-catenin and YAP signaling in the syngeneic
murine B16-F10 and Clone M-3 melanoma models and sensitizes the tumors to anti-PD-1
immune checkpoint therapy. Mechanistically, we demonstrate that the synergistic effect of
tankyrase and checkpoint inhibitor treatment is dependent on loss of β-catenin in the tumor
cells, anti-PD-1-stimulated infiltration of T cells into the tumor and induction of an IFNγ- and
CD8+ T cell-mediated anti-tumor immune response. Our study uncovers a combinatorial
therapeutical strategy using tankyrase inhibition to overcome β-catenin-mediated resistance
to immune checkpoint blockade in melanoma.
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Cancer immunotherapy is undergoing rapid advances.Treatment of patients using immune checkpoint inhibi-tors, such as antibodies against cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed cell death 1 (PD-1)
and programmed death-ligand 1 (PD-L1) that enhance T cell-
mediated immune responses against cancer, is considered a major
breakthrough1,2. However, many cancer patients, including
40–65% of melanoma patients, do not respond to checkpoint
inhibitor treatment and the underlying mechanisms are not well
understood1–4. Resistance mechanisms are currently being map-
ped, and cellular signaling pathways and components, such as
epidermal growth factor receptor (EGFR), phosphoinositide-3-
kinase (PI3K)/AKT serine/threonine kinase (AKT), vascular
endothelial growth factor (VEGF) and B-Raf proto-oncogene,
serine/threonine kinase (BRAF)V600E, as well as Wingless-type
mammary tumor virus integration site (WNT)/β-catenin signal-
ing, emerge as promising targets for therapeutical intervention1,5,6.
WNT/β-catenin signaling can play a central regulatory role in
immune cell homeostasis, development and function as well as in
peripheral T cell activation, differentiation and tumor-immune
cell interplay7. β-catenin is the key transcriptional regulator
of WNT/β-catenin signaling8. β-catenin-induced immune
evasion is found in 13% of all tumors9 and 42% of cutaneous
melanoma10.
A recent study, using genetically engineered murine melanoma
models, revealed that tumors expressing a dominant stable form
of β-catenin showed negligible T-cell infiltration and were resis-
tant to checkpoint blockade therapy11. In these β-catenin-positive
tumors, production of C–C motif chemokine ligand 4 (CCL4)
and additional chemokines was reduced. This, at least partly12,
resulted in reduced recruitment of cluster of differentiation (CD)
103+/ basic leucine zipper transcriptional factor ATF-like 3
(BATF3)-lineage dendritic cells (DC) to the tumor micro-
environment and finally defective host priming of antigen-specific
T cells11,13. In contrast, in melanoma tumors with low levels of β-
catenin, DCs and CD8+ T cells migrated into the tumor and the
tumor-killing activities of CD8+ T cells could be unleashed or
enhanced by the use of checkpoint inhibitors11. Hence, inter-
ventions that reduce WNT/β-catenin signaling may have the
potential to broaden the anti-tumor spectrum of checkpoint
inhibitors.
Although dysregulation of WNT signaling is a hallmark
characteristic in a major fraction of cancers, anti-cancer therapy
that targets this pathway is currently not available in clinical
practice8,14–16. Target identification and characterization of the
small-molecular WNT/β-catenin signaling inhibitor XAV939
revealed that telomeric repeat factor (TRF1)-interacting ankyrin-
related ADP-ribose polymerases 1 and 2 (tankyrase 1 and 2,
TNKS1/2) are key and druggable regulatory enzymes in the sig-
naling pathway17. TNKS1/2 catalyze the post-translational mod-
ification poly(ADP-ribosyl)ation. AXIN1 and AXIN2 proteins are
the main rate-limiting structural proteins that together with
adenomatous polyposis coli (APC) control the formation of the
β-catenin degradosome, which also contains the β-catenin-
targeting kinase glycogen synthase kinase 3 beta (GSK3β)18.
TNKS1/2 poly(ADP-ribosyl)ate AXIN proteins to earmark them
for degradation by the ubiquitin-proteasomal system19. Inhibition
of TNKS1/2 can therefore lead to stabilization of AXIN proteins
and hence the degradosomes. This, in turn, enhances the phos-
phorylation and degradation of the central transcriptional reg-
ulator β-catenin and inhibits WNT/β-catenin signaling17,20–23.
TNKS1/2 catalytic activity does not only regulate the stability
of AXIN proteins, but also interferes with additional biological
mechanisms and cell signaling pathways including telomere
homeostasis, mitotic spindle formation, vesicle transport, and
energy metabolism, as well as AKT/PI3K, AMPK and Hippo
signaling19,24–26. In Hippo signaling, tankyrase inhibitor-
mediated stabilization of angiomotin (AMOT) proteins shifts
the subcellular location of the transcription cofactors yes asso-
ciated protein 1 (YAP) and tafazzin (TAZ), leading to a reduction
of oncogenic YAP signaling27,28. Recent reports show that YAP
signaling may support immune evasion in cancer and melanoma
by inducing PD-L1 expression29,30, whereas others show that
enhanced YAP signaling, due to loss of the regulating kinases
large tumor suppressor kinase 1 and 2 (LATS1/2), may promote
an anti-cancer immune response31.
Checkpoint inhibitor treatment, including blockade of the PD-
1 receptor, has shown limited efficacy in the murine B16-F10
melanoma model, despite strong expression of the ligand PD-L1
on the tumor cells32; a feature attributed to low tumor infiltration
by effector CD8+ T cells33,34. G007-LK is a potent preclinical
stage tankyrase inhibitor with a high selectivity towards tankyrase
1 and 2 and a favorable pharmacokinetic profile in mice with an
oral bioavailability of 76% and a t1/2 of 2.6 hours in female
mice23,35,36.
Here, we describe G007-LK-mediated blockade of both WNT/
β-catenin and YAP signaling in B16-F10 cells in vitro and in vivo.
We show that two murine melanoma models display resistance to
monotherapy with either anti-PD-1 or G007-LK. A synergistic
anti-tumor effect was observed upon combined anti-PD-1/G007-
LK treatment. We show that the mechanistic basis for the synergy
was not G007-LK-mediated enhanced release of the BATF3-
lineage DC-attracting chemokine CCL4 or increased tumor
infiltration by CD8+ T cells. Instead, we find that alterations in T
cell infiltration are mainly orchestrated by anti-PD-1 treatment
alone. Next, we provide evidence that combined anti-PD-1/G007-
LK treatment of B16-F10 tumors is effectuated by G007-LK-
induced loss of β-catenin in the tumor cells and induction of an
interferon-γ (IFNγ)- and CD8+ T cell-dependent anti-tumor-
immune response. Finally, upon RNA sequencing of G007-LK-
treated human melanoma cell lines and B16-F10 cells, we reveal a
transcriptional response profile for a cell line subpopulation
displaying high relative baseline YAP signaling activity and pre-
disposition for reduced MITF expression upon tankyrase
inhibition.
Results
G007-LK inhibits WNT/β-catenin and YAP signaling. Tan-
kyrase inhibition can inhibit proliferation and viability in a subset
of cancer cell lines in vitro8,25. When the anti-proliferative effect
of G007-LK on cultured B16-F10 mouse melanoma cell line was
monitored, only a limited cell growth reduction was observed
(Supplementary Fig. 1a, b). Efficacy of G007-LK treatment on
WNT/β-catenin and YAP signaling in B16-F10 cells was then
explored in vitro and in vivo. In cell culture, G007-LK-treated
B16-F10 cells displayed stabilization of TNKS1/2 and AXIN1
proteins (Fig. 1a, Supplementary Fig. 2a and Supplementary
Fig. 27), as well as formation of cytoplasmic TNKS1/2-containing
puncta (Supplementary Fig. 3), indicating the formation and
accumulation of β-catenin degradosomes22,23,37.
Moreover, in WNT3a-induced B16-F10 cells, G007-LK treat-
ment reduced the level of nuclear and cytoplasmic β-catenin
protein, transcription of the WNT/β-catenin signaling target
genes, such as Axin2 and transcription factor 7 (Tcf7) and also
luciferase-based WNT/β-catenin signaling reporter activity
(Fig. 1a–c and Supplementary Figs. 2b, c, 4a, c, 5b, 27 and
Supplementary Table 1a, b). No distinct effect of G007-LK on
WNT/β-catenin signaling was observed in neither B16-F10 cells
without WNT3a stimulation nor in β-catenin knockout cells
(B16-F10Ctnnb1KO), indicating low endogenous pathway activity
in vitro (Fig. 1a–c, Supplementary Figs. 4a, 5a–e and
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Supplementary Table 1a, b). Treatment with G007-LK was unable
to counteract luciferase-based WNT signaling reporter activity
rescued by overexpression of N-terminal mutated β-catenin in
B16-F10Ctnnb1KO cells (Supplementary Fig. 5f). These results
suggest that tankyrase inhibition only induces turn-over of wild-
type β-catenin containing intact GSK3β phosphorylation sites.
G007-LK treatment also stabilized angiomotin like 1
(AMOTL1) and angiomotin like 2 (AMOTL2) proteins and
decreased transcription of YAP signaling target genes, such as
cellular communication network factor 1 (Ccn1, previously
named Cyr61), cellular communication network factor 1 (Ccn2,
previously named Ctgf), Amotl2 and YAP signaling luciferase
reporter activity (Supplementary Figs. 4b, 6a–c, 28 and
Supplementary Table 1a,b). The nuclear YAP protein level,
instead of being reduced upon tankyrase inhibition as previously
reported27,38, actually increased in both B16-F10 and HEK293
cells upon G007-LK treatment (Supplementary Fig. 6a, d and 28).
Confocal imaging further revealed that G007-LK treatment
induced the aggregation of puncta, predominantly in the
cytoplasma, with not only colocalized AMOTL1-YAP and
AMOTL2-YAP but also AMOTL1-TNKS1/2 and AMOTL2-
TNKS1/2 (Supplementary Fig. 7a, b).
Next, C57BL/6 N mice with established B16-F10 tumors were
treated with G007-LK for four days. This treatment destabilized
TNKS1/2 and stabilized AXIN1 protein levels, similar to previous
reports23, and decreased β-catenin protein levels as well
transcription of WNT/β-catenin target genes in the tumors
(Fig. 2a, b and Supplementary Figs. 8 and 29). In parallel,
AMOTL2 protein was stabilized and transcription of the YAP
signaling target genes Ccn1, Ccn2, and Amotl2 were reduced in
the tumors (Supplementary Figs. 9a–c and 29).
These results show that tankyrase inhibitor treatment using
G007-LK can attenuate WNT/β-catenin signaling and YAP
signaling target gene expression in B16-F10 cells in vitro and
in vivo.
Synergistic tankyrase and PD-1 inhibition treatment effect. To
test whether tankyrase inhibition can counteract resistance to
immune checkpoint blockade, B16-F10 tumors were established
subcutaneously in C57BL/6 N mice. Neither monotherapy with
G007-LK, PD-L1 nor PD-1-blocking antibodies reduced tumor
size. However, combined anti-PD-1/G007-LK treatment, but not
the anti-PD-L1/G007-LK combination, reduced tumor volume
and weight (Fig. 3a and Supplementary Fig. 10a–e). In addition,
the combined anti-PD-1/G007-LK treatment also reduced WNT/
β-catenin signaling and tumor volume of murine Clone M-3Z1
melanoma in immunocompetent DBA/2 N mice (Fig. 3b, Sup-
plementary Figs. 11a, c-f and 29). No signs of toxicity, intestinal
injury (Supplementary Fig. 10g) or change in body weights were
observed in any of the mouse experiments (Supplementary
Figs. 10f and 11b). To examine longer-term efficacy of combined
anti-PD-1/G007-LK treatment, B16-F10-bearing C57BL/6 N mice
were followed until the entire control group reached the endpoint
criterion. In the three surviving anti-PD-1/G007-LK-treated mice
(18.5%) (Fig. 3c and Supplementary Fig. 12a–d), histopathologi-
cal evaluation of immunostained tumor sections detected no
viable tumor cells. Instead, the tumor implant site was infiltrated
by macrophages loaded with melanin, presumably derived from
B16-F10 cells (Fig. 3d).
In summary, the tested murine melanoma models are resistant
to single-agent anti-PD-1 or G007-LK treatment. In contrast, a
synergistic anti-tumor effect and eradication of a subset of the
tumors was observed upon combined anti-PD-1/G007-LK
treatment.
Tankyrase inhibition alters intratumoral cytokine composi-
tion. We next pursued the mechanistic basis for the observed
synergy of anti-PD-1 and G007-LK treatment. Previous work in a
genetically modified mouse melanoma model have indicated that
decreased WNT/β-catenin signaling in the tumor cells promoted
adaptive immune responses within the tumor by enhanced
secretion of the cytokine CCL47,11. The subsequent chemotaxis of
dendritic cells to the tumor site was reported to support infil-
tration and activation of tumor-reactive CD8+ T cells11. To
identify alterations in cytokine secretion upon treatment, condi-
tioned supernatants from matrigel-embedded B16-F10 tumors39
Fig. 1 G007-LK can reduce WNT/β-catenin signaling in B16-F10 cells in vitro. a Representative immunoblots of cytoplasmic AXIN1 (upper) and nuclear
active form of β-catenin (non-phospho, serine [Ser] 33/37/threonine [Thr] 41) and total β-catenin (lower). GAPDH or lamin B1 document equal protein
loading. Treatments used for cultured B16-F10 cells in a–c: Vehicle (DMSO, 0.01%), G007-LK (1 µM), recombinant WNT3a (activator of WNT/β-catenin
signaling) or WNT3a+G007-LK for 24 h. b Luciferase-based reporter assay for measuring WNT/β-catenin signaling activity. B16-F10 cells transiently
transfected with superTOPflash (vector with TCF promoter binding sites) or FOPflash (control vector with mutated TCF binding sites) along with Renilla
luciferase (for normalization). All samples normalized to superTOPflash signal for wild-type control. For b, c Boxplots show median, first and third quartiles
and maximum and minimum whiskers. One-tailed t-tests are indicated by *(P < 0.05) or **(P < 0.01). Background SuperTOPflash versus FOPflash activities
were not significantly different, indicating low basal WNT/β-catenin signaling activation. One representative experiment of two repeated assays with three
replicates is shown. c Real-time RT-qPCR analyses of WNT/β-catenin signaling target genes (Axin2 and Tcf7). One-tailed t-test is indicated by **(P < 0.01)
and one-tailed Mann-Whitney rank sum tests are indicated by †(P < 0.05). Combined data from minimum three independent experiments with three
replicates each are shown.
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were screened using multiplex immunoassays while cell cultures
were analyzed using ELISA assays. Few alterations were detect-
able in anti-PD-1-treated tumors, however, G007-LK treatment
was associated with increased levels of three cytokines and
decreased levels of five cytokines (>30% difference compared to
control) (Fig. 4a and Supplementary Fig. 13). Similar changes in
cytokine secretion were apparent upon anti-PD-1/G007-LK
treatment (Fig. 4a and Supplementary Fig. 13). Notably, G007-LK
treatment reduced CCL4 levels in B16-F10 tumors (Fig. 4b) but
no reduction was detected in cultured B16-F10 cells (Fig. 4c). Ccl4
transcript was not inversely correlated to its previously described
negative regulator activating transcription factor 3 (Atf3)11 in
either wild-type B16-F10 cells or B16-F10Ctnnb1KO cells when
compared to wild-type cells (Fig. 4d, e).
In conclusion, the results suggest that G007-LK treatment, but
not anti-PD-1 treatment, mainly alters the intratumoral cytokine
composition. The herein observed anti-PD-1/G007-LK-induced
anti-tumor effect cannot be attributed to enhanced CCL4 secretion.
The treatment effect depends on β-catenin in tumor, IFNγ, and
CD8+ T cells. A knockout of β-catenin in B16-F10 cells can serve
as a model to recapitulate G007-LK-mediated blockade of WNT
signaling. To evaluate β-catenin-mediated immune evasion in the
B16-F10 syngeneic mouse melanoma model, β-catenin was
knocked out in B16-F10 cells (B16-F10Ctnnb1KO, Supplementary
Fig. 5a, b) and one of the cell lines, B16-F10Ctnnb1KO1, was used to
establish subcutaneous tumors in C57BL/6 N mice. Compared to
vehicle control mice, anti-PD-1-treated mice displayed reduction
in tumor size, indicating loss of anti-PD-1 resistance in β-catenin-
deficient tumors (Fig. 5a and Supplementary Fig. 14a–d). The
result suggests that the synergistic anti-PD-1/G007-LK treatment
effect seen in wild-type B16-F10 tumors (Fig. 3a) is, to a con-
siderable part, attributed to G007-LK-induced reduction of β-
catenin levels in the melanoma cells of the tumors.
To evaluate if the observed effects of anti-PD-1/G007-LK
treatment are mediated by an adaptive immune response, B16-
F10 challenge experiments were repeated in recombinase-
deficient (Rag2−/−) mice, which lack functional T and B cells,
but possess functionally intact natural killer (NK) cells40. No
significant effect of anti-PD-1/G007-LK treatment was observed
in such mice (Fig. 5b and Supplementary Fig. 15a, b). Although, a
contributory role of NK cells and the innate immune system
cannot be entirely excluded, the result indicates that the anti-PD-
1/G007-LK treatment effect is orchestrated by an adaptive
immune response.
Next, we further evaluated the adaptive immune response by
performing selective elimination of either CD8+ T cells or IFNγ.
Antibody-mediated CD8+ T cell depletion abrogated the anti-
tumor effect of anti-PD-1/G007-LK treatment (Fig. 5c and
Supplementary Fig. 16a, b). Similarly, neutralization of IFNγ
resulted in increased tumor growth comparable to anti-PD-1/G007-
LK -treated mice (Fig. 5c and Supplementary Fig. 16a, b). In
summary, these results confirm a role of CD8+ T cells and IFNγ as
mediators of the synergistic effect of anti-PD-1/G007-LK treatment.
To assess immune cell infiltration upon treatment, we next
performed flow cytometry analysis using tumors of comparable
size collected on day 7–17 (Supplementary Figs. 17a and 18a, b).
No increase in tumor leukocyte abundance was observed in any
of the treatment groups when compared to the control group
(Supplementary Fig. 17b). An increase in total T cell and CD8+ T
cell infiltration was seen in both the anti-PD-1 and anti-PD-1/
G007-LK groups, whereas CD4+ T cells were similarly increased
across all treatment groups (Fig. 5d and Supplementary Fig. 17c).
No differences in the abundance of CD4+ or CD8+ T cells
expressing the memory marker CD44 were detected (Supple-
mentary Fig. 17d). Tregs constituted approximately 1% of
infiltrating CD45+ cells in all groups (Supplementary Fig. 17e).
Myeloid DCs were decreased in the anti-PD-1 and anti-PD-1/
G007-LK-treated groups while CD103+ DCs were equally present
in all treatment groups (Supplementary Fig. 17f). Lymphoid DCs,
myeloid-derived suppressor cells (M-MDSC) and neutrophils
were present at comparable levels across all treatment groups
(Supplementary Fig. 17g).
Subsequently, infiltration of CD8+ T cells in tumors sections
was scored using treated wild-type and β-catenin knock-out B16-
F10 tumors. Only anti-PD-1 and anti-PD-1/G007-LK-treated
B16-F10Ctnnb1KO tumors showed an increase in CD8+ T cell
infiltration when compared with controls (Fig. 5e and Supple-
mentary Fig. 19). The result suggests that only PD-1 inhibition,
and not loss of β-catenin in the tumor cells, contributes to
increased chemotaxis of CD8+ T cells.
To evaluate direct effects of G007-LK on T cell effector
functions, we assayed the in vitro activation of MHC class I (H2-
Kb)-restricted and ovalbumin-specific CD8+ T cells. The
presence of G007-LK moderately enhanced T cell proliferation
Fig. 2 G007-LK can reduce WNT/β-catenin signaling in B16-F10 tumors in C57BL/6N mice. a Representative quantified protein immunoblot ratios
(protein vs. loading control) from whole subcutaneous (s.c.) B16-F10 tumors showing altered expression of TNKS1/2, AXIN1, active form of β-catenin (non-
phospho, Ser33/37/Thr41) and β-catenin (total). Mean values are indicated by grey lines. For a and b upon 4 days of treatment with G007-LK diet (n= 8,
except n= 7 for AXIN1) compared to controls (n= 8). Two-tailed t-tests are indicated by *(P < 0.05) and two-tailed Mann-Whitney rank sum tests are
indicated by ‡(P < 0.01). b Real-time RT-qPCR analyses of WNT/β-catenin signaling target genes (Axin2 and Tcf7). One-tailed t-test is indicated by **(P <
0.01) and one-tailed Mann-Whitney rank sum test is indicated by ‡(P < 0.01). Boxplots show median, first and third quartiles and maximum and minimum
whiskers for combined data from two independent measurements with three replicates each are shown.
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following cognate interaction with antigen-presenting cells, but
did not affect proliferation following polyclonal activation by
immobilized anti-CD3/anti-CD28 antibodies (Supplementary
Fig. 20a). The presence of G007-LK did not affect the expression
of T cell activation markers (CD26L, CD44, CD25, and CD69) or
secretion of interleukin 2 (IL2) or IFNγ (Supplementary
Fig. 20b–d). The addition of G007-LK induced a slight increase
in intracellular granzyme B expression in CD8+ T cells following
cognate or polyclonal activation, possibly indicating increased
effector function (Supplementary Fig. 20e).
In summary, combined anti-PD-1/G007-LK treatment of B16-
F10 tumors is dependent on tankyrase inhibitor-mediated loss of
β-catenin in the tumor and induces an IFNγ and CD8+ T cell-
dependent growth-inhibitory effect. Changes in myeloid DC and
T cell infiltration are likely attributable to anti-PD-1 treatment,
but do not alone seem to cause anti-tumor activity.
RNA sequencing reveals a subpopulation transcriptional
response profile. The efficiency of tankyrase inhibitor-mediated
inhibition of WNT/β-catenin and YAP signaling is known to be
cell type and context-dependent. The beneficial synergistic anti-
PD-1/G007-LK treatment effect seen on immunosurveillance in
B16-F10 tumors may therefore vary between melanomas based
on differences in cell signaling pathway activities and genetic
background. In addition, the here utilized B16-F10 murine mel-
anoma model, lacking the BRAFV600E mutation41,42, only par-
tially recapitulates the genetic features of human melanoma.
Thus, murine B16-F10 cells and a panel of 18 human melanoma
cell lines, were exposed to G007-LK treatment followed by RNA
sequencing and bioinformatic analyses.
In the untreated group, no clear correlation was found between
baseline transcription of WNT/β-catenin signaling target genes
(Supplementary Fig. 21a) or the mutation load (Supplementary
Fig. 3 Dual inhibition of tankyrase and PD-1 confers synergistic anti-tumor efficacy in mouse melanoma. a B16-F10 tumor (s.c.) end volume upon anti-
PD-1/G007-LK treatment (−83% when compared to control) in C57BL/6 N mice treated from day 10 through 21. Control diet (n= 10), G007-LK diet (n=
10), anti-PD-1 (n= 11), and anti-PD-1/G007-LK (n= 8). Mann-Whitney rank sum tests are indicated by †(P < 0.05) and ‡(P < 0.01). For a, b Mean values
are indicated by grey lines. Absence of depicted statistical comparisons indicates lack of statistical significance. b Clone M-3Z1 tumor (s.c.) end volume
reduction upon anti-PD-1/G007-LK treatment (−53% when compared to control) in DBA/2N mice treated from day 8–18. Control diet (n= 8), G007-LK
diet (n= 8), anti-PD-1 (n= 11), and anti-PD-1/G007-LK (n= 10). Two-tailed t-test is indicated by *(P < 0.05). c Kaplan-Meier plot showing survival of B16-
F10-recipient (s.c.) C57BL/6N mice treated with control diet (n= 19, blue) or anti-PD-1/G007-LK (n= 16, black) from day 10 to 38. Difference between
the two graphs: One-tailed log rank (Mantel-Cox) test, P= 0.087, hazard ratio= 1.75, 95% CI: 0.78–3.93. d Representative images from H&E (left and
middle panels) and F4/80 and Hoechst-stained (in green and blue, respectively, right panels) tumors from control (n= 5, upper panels) and tumor implant
sites of anti-PD-1/G007-LK-treated surviving mice (n= 2, lower panels). Macrophages laden with melanin are highlighted with arrows. Scale bars: H&E=
100 µm (original magnification × 100) and H&E higher magnification and F4/80 Hoechst= 50 µm (original magnification × 400).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0916-2 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:196 | https://doi.org/10.1038/s42003-020-0916-2 | www.nature.com/commsbio 5
Fig. 22) against overall gene expression (Supplementary Fig. 21b,
c). However, when the cell lines were classified into two groups
based on baseline YAP signaling target gene transcription,
YAPhigh and YAPlow (Fig. 6a), the YAPhigh group coincided with
clustering of overall gene expression and against a panel of
markers for β-catenin-controlled melanoma cell fate and
proliferation43 (Supplementary Fig. 21d–f). One of these markers
in the YAPhigh group, melanocyte inducing transcription factor
(MITF), had an overall low relative transcription profile (MIT-
Flow) (Fig. 6b). MITF is a lineage-restricted regulator in
melanocytes that is positively associated with melanoma
proliferation, and also suppressed invasion and metastasis44–46.
Indeed, when using untreated samples, ingenuity pathway
analysis (IPA) core analysis of the YAPhigh versus the YAPlow
group identified MITF as the most statistically significant key
upstream transcriptional regulator separating the two groups
(Supplementary Fig. 23a, b and Supplementary Table 2).
Upon treatment with G007-LK, samples in the MITFlow group
were predisposed for decreased MITF expression (MITFdecreased),
while the MITFhigh group was oppositely predisposed for
increased MITF expression (MITFincreased)(Fig. 6b and Supple-
mentary Fig. 24a). Notably, in B16-F10 tumors, transcription of
Mitf was moderately reduced upon G007-LK-treatment (Fig. 6c).
Attenuated WNT/β-catenin and/or YAP signaling activity was
observed in nearly all samples upon G007-LK treatment (Fig. 6d).
These changes in signaling pathway activities did not correlate
with changes in MITF expression, nor act as a predictive marker
for MITF regulation (Fig. 6e and Supplementary Figs. 24b–e and
25a, b). In conclusion, YAPhigh is a marker for a melanoma
subgroup that includes B16-F10 (Fig. 6e) and tracks with
tankyrase inhibitor-induced reduction in MITF expression
(Supplementary Fig. 26 and Supplementary Table 3).
Discussion
Here we show, for the first time to our knowledge, proof-of-
concept results for a previously unreported therapeutic strategy
using tankyrase inhibitor-mediated blockade of WNT/β-catenin
signaling to counteract β-catenin-supported immune evasion and
resistance to checkpoint inhibition in syngeneic murine mela-
noma models.
The G007-LK treatment effect could be recapitulated in vivo by
knockout of β-catenin in B16-F10 tumor cells. Although not
further supported by a rescue experiment re-introducing N-
terminal mutant β-catenin, the result suggests that loss of WNT/
β-catenin signaling in tumor cells is sufficient to trigger a gain of
susceptibility and a synergetic relationship to checkpoint inhibi-
tion. Nevertheless, we cannot exclude the possibilities that
Fig. 4 Tankyrase inhibition modulates cytokine release in B16-F10 tumors. a Mean values (pg/mL) for enhanced release of chemokines (by >30% over
control, highlighted in pink) and downregulated cytokines and chemokines (by >30% below control, highlighted in blue) are shown. For a, b Conditioned
supernatants from matrigel-embedded s.c. B16-F10 tumors screened using multiplex immunoassay upon treatment from day 6 through day 14. Treatments:
Control diet (n= 3), G007-LK diet (n= 6), anti-PD-1 (n= 5), and anti-PD-1/G007-LK (n= 8). *indicates samples measured using ELISA in b. b CCL4
ELISA measurements using supernatants from B16-F10 tumors. Two-tailed t-tests are indicated by *(P < 0.05) and **(P < 0.01). Mean values from one
representative experiment of three repeated measurements are indicated by grey lines. c CCL4 ELISA assay using supernatants from in vitro cultured (72
h) B16-F10 wild-type cells treated with vehicle control (DMSO, 0.01%), G007-LK (1 µM), WNT3a, WNT3a+G007-LK as well as B16-F10Ctnnb1KO cells
(KO1 and 2) treated with G007-LK (1 µM). Positive control, recombinant CCL4 protein. Negative control: H2O. For c–e Boxplots show median, first and
third quartiles and maximum and minimum whiskers. One representative experiment of two repeated assays with three replicates is shown. d Real-time
RT-qPCR analyses of Atf3 and Ccl4 from B16-F10 cell culture treated (24 h) with vehicle control (DMSO, 0.01%) or G007-LK (1 µM). For d, e Combined
data from minimum three independent experiments with three replicates each are shown. Two-tailed t-test is indicated by **(P < 0.01), two-tailed Mann-
Whitney rank sum test is indicated by ‡(P < 0.01) and n.s. not significant. e Real-time RT-qPCR analyses of Atf3 and Ccl4 from cultured B16-F10Ctnnb1KO
cells compared to wild-type B16-F10 cells.
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tankyrase inhibition impacts additional biological mechanisms in
the tumor cells, in the tumor microenvironment, systemically or
on immune cell subpopulations that can contribute to the treat-
ment effect7,19,24,25. In addition to its effect on WNT/β-catenin
signaling, G007-LK treatment stabilized AMOT proteins and
reduced YAP signaling-mediated gene expression in B16-F10 cell
culture and tumors. An absence of reduced nuclear YAP and TAZ
protein levels, as also seen in HEK293 cells, along with the here
observed aggregation of colocalized YAP, AMOT proteins and
TNKS1/2-containing puncta, is inconsistent with previous reports
indicating that further evaluation of tankyrase inhibitor-induced
interference with YAP signaling is necessary27,37,38.
Our results provide evidence that the anti-tumor effect of
combined tankyrase and checkpoint inhibitor treatment against
B16-F10 tumors is dependent on both IFNγ and CD8+ T cells
and occurs, at least in part, through direct suppression of WNT/
β-catenin signaling within the tumor cells. The precise mechan-
istic basis of this synergistic effect remains to be investigated.
Previous work performed in genetically modified models indicate
that lowered WNT/β-catenin signaling11 resulted in increased
intratumoral CCL4 cytokine release, which lead to enhanced
influx of CD103+/BATF3+ pDCs and subsequent activation of
CD8+ T cell anti-tumor activity. Our results indicate that G007-
LK treatment indeed could change the intratumoral cytokine
composition; however, we found no evidence for increased CCL4
cytokine levels. In addition, assessment of the intratumoral
immune response following G007-LK monotherapy did not yield
significant quantitative alterations in T cell or antigen-presenting
cell (APC) subsets in treated mice. While it cannot be excluded
that qualitative or more subtle quantitative changes in particular
tumor-specific CD8+ T cell subsets might be responsible for the
observed therapeutic effects, an increase in overall CD8+ T cell
infiltration was not observed. Only a moderate enhancement of
proliferation and granzyme B expression was observed in G007-
LK-treated MHC class I (H2-Kb)-restricted and ovalbumin-
specific CD8+ T cells, which could indicate enhanced effector
function. In depth follow-up studies in the framework of tan-
kyrase inhibition are required, including assessment of the effects
of alterations in individual cytokine and chemokine levels on the
T cell response12. The use of model systems with defined and
Fig. 5 The synergistic anti-tumor effect of tankyrase and PD-1 inhibition is recapitulated by β-catenin depletion in tumor cells and is dependent on
IFNγ and CD8+ T cells. a, B16-F10Ctnnb1KO tumor (s.c.) end volume reduction upon anti-PD-1 (−78%) and combined anti-PD-1/G007-LK treatment
(−90%) in C57BL/6 N mice treated from day 11 through day 25. Control diet (n= 9), G007-LK diet (n= 9), anti-PD-1 (n= 10), and anti-PD-1/G007-LK
(n= 10). Mann-Whitney rank sum tests are indicated by †(P < 0.05) and ‡(P < 0.01). For a–e Mean values are indicated by grey lines. b Tumor end
volumes of B16-F10-challenged (s.c.) C57BL/6 Rag2−/− mice treated for 12 days with control diet (n= 11) compared to combined anti-PD-1/G007-LK
treatment (n= 10). n.s. not significant. c B16-F10 tumor (s.c.) end volume reduction upon anti-PD-1/G007-LK treatment in C57BL/6 N mice from day 10
through day 21. Control diet (n= 11), anti-IgG1 isotype control (n= 12), anti-IgG2 isotype control (n= 10), anti-CD8α (n= 10), anti-IFNγ (n= 9), anti-PD-
1/G007-LK (n= 10), anti-PD-1/G007-LK /anti-CD8α (n= 9), and anti-PD-1/G007-LK /anti-IFNγ (n= 9). One-tailed t-tests are indicated by *(P≤ 0.05)
while one-tailed Mann-Whitney rank sum test is indicated by †(P < 0.05). d Flow cytometry analysis of CD8+ and CD4+T cells (shown as % of CD45+
T cells) from single-cell suspensions of comparable-sized tumors collected from B16-F10-challenged (s.c.) C57BL/6 N mice treated for 7–17 days with
control diet (n= 14), G007-LK diet (n= 13), anti-PD-1 (n= 14) or anti-PD-1/G007-LK (n= 13). Two-tailed t-tests are indicated by *(P < 0.05) and **(P <
0.01). e CD8+ T cell counts from IHC sections from s.c. wild-type B16-F10 tumors (control diet [n= 5], G007-LK diet [n= 4]), and B16-F10Ctnnb1KO tumors
(control diet [n= 7], G007-LK diet [n= 8]) anti-PD-1 [n= 10] and anti-PD-1/G007-LK [n= 9]). Two-tailed t-tests are indicated by *(P < 0.05) and one-
tailed Mann-Whitney rank sum test is indicated by ‡(P < 0.01).
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traceable anti-tumor CD8+ T cell specificities would also be of
value in determining the effects of tankyrase inhibition on the
kinetics and qualitative characteristics of the ensuing immune
response.
The RNA sequencing of 18 tankyrase inhibitor-treated human
melanoma cell lines and B16-F10 cells shows that tankyrase
inhibition context-dependently can influence WNT/β-catenin
and YAP signaling, not only in murine B16-F10 cells, but
importantly also in a subset of 18 human melanoma cell lines.
The results indicate that tankyrase inhibition may have a
potential for treatment of a subset of patients with the human
disease in combination with checkpoint inhibition. Analysis of
the RNA sequencing data revealed a subgroup-specific tran-
scriptional response profile. Upon tankyrase inhibition, the sub-
group displaying elevated baseline YAP signaling activity was
susceptible to reduced MITF expression. Presently, neither the
meeting points between MITF, its regulation by YAP/ TEA
domain transcription factor (TEAD), activator protein 1 (AP-1)
Fig. 6 High activity of YAP signaling correlates with low baseline MITF expression and potential for decreased MITF transcription upon tankyrase
inhibition. a Expression of YAP signaling target transcripts (Ccn1, Ccn2, and Amotl2) for untreated human and murine B16-F10 melanoma cell lines. Seven of
19 samples displayed high relative transcription of YAP signaling target genes (YAPhigh) when compared to samples with less transcription (YAPlow).
YAPhigh is highlighted by orange branches in the dendrogram and arrows. Scale bar indicates differences in Z-score (standard deviations < or > mean)
values for log2 transcripts per millions (TPMs) within each row. Cancer stages: Metastatic in blue, radial growth phase (RGP) in pink and vertical growth
phase (VGP) in green. b Baseline MITF expression in untreated samples (grey bars, log2-transformed TPMs × 10−1) and change upon treatment with
G007-LK (1 µM) for 24 h (black dots sorted descending from left to right, log2 values from treated versus untreated TPMs). Samples with increased
(MITF increased, left) or decreased (MITF decreased, right) expression of MITF upon tankyrase inhibitor treatment are separated by scattered vertical line.
*Indicates that no value for untreated sample is inserted. For b, d B16-F10 WNT3a=WNT3a+G007-LK relative to WNT3a-stimulated control. YAPhigh
cell lines are highlighted by orange arrows. c Real-time RT-qPCR analysis of Mitf expression in G007-LK-treated B16-F10 s.c. tumors versus control tumors
(n= 8). Two-tailed Mann-Whitney rank sum test is indicated by ‡(P < 0.01). Boxplot shows median, first and third quartiles and maximum and minimum
whiskers for data from two repeated measurements. d Changes in gene expression for WNT/β-catenin (Axin2 and Tcf7) and YAP (Ccn1, Ccn2, and Amotl2)
signaling target genes for 18 G007-LK-treated (1 µM) human and murine B16-F10 melanoma cell lines. Downregulated signaling activity is indicated by
↓ (log2 <−0.2, highlighted in blue), upregulated activity is indicated by ↑ (log2 > 0.2, highlighted in pink), and inconclusive or lack of regulation is indicated
by− . e Venn diagram depicting the cell lines intersecting profiles for pre-treatment (YAPhigh and MITF low) and response to G007-LK treatment
(MITF decreased and YAP or WNTdecreased).
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and tankyrase, nor the function in immune regulation and con-
trol of susceptibility to checkpoint‐inhibitor therapy are well
characterized46–51. Further molecular and functional evaluations
are required for establishing a precise set of rules for context-
dependent treatment efficiency using combined tankyrase and
checkpoint inhibitor treatment in human melanoma. Translation
of the combinatorial therapeutical strategy, using tankyrase
inhibition to counteract β-catenin-induced resistance to immune
checkpoint blockade, should also be evaluated for treatment
efficacy against other cancers6,7,9.
Tankyrase inhibitors have been suspected to cause intestinal
toxicity23 and bone loss52 in certain mouse models. In this study,
and similar to previous reports22,36,53, we observed no signs of
toxicity, intestinal injury or body weight changes in G007-LK-
treated mice. G007-LK is a preclinical stage tankyrase inhibitor
without the properties needed to reach approval for clinical
testing35. Currently, extensive research to identify and further
develop safe drugs directed towards multiple biotargets in the
WNT signaling pathway, including tankyrase, are ongoing8,14–16.
Collectively, the results presented here suggest that G007-LK-
induced blockade of WNT/β-catenin signaling leads to improved
efficacy of PD-1 immune checkpoint blockade, and in addition
induction of an IFNγ and CD8+ T cell-dependent anti-tumor-
immune response against B16-F10 tumors. The find-
ings warrant a further in-depth preclinical and clinical evaluation
of combining checkpoint inhibitors with tankyrase inhibition for
the treatment of melanoma.
Methods
Cell culture. The mouse melanoma cell line B16-F10 (ATCC® CRL-6475™) and
human HEK293 cells (ATCC® CRL-1573™) were obtained from the American Type
Culture Collection. Clone M-3Z1 (ProQinase) cells were derived from Clone M-3
cells (ATCC® CCL-53.1™) after implantation in DBA/2 NCrl mice (DBA/2N,
Charles River). The cell cultures were generally kept below 20 passages (~10 weeks)
and the melanoma cells were grown in RPMI-1640 medium (R8758, Sigma
Aldrich) while HEK293 cells were grown in DMEM medium (D6429, both Sigma
Aldrich). The cell culture medium was supplemented with 1% penicillin-
streptomycin (P4333, Sigma Aldrich) and 5% fetal bovine serum (FBS, 10270-106,
Gibco) and grown at 37 °C in humidified incubators with 5% CO2. The cells were
routinely monitored (upon thawing and monthly) for mycoplasma using
MycoAlert mycoplasma detection kit (Lonza). B16-F10 cells were authenticated by
short tandem repeat profiling and subsequent analysis confirming murine C57BL/6
origin (Leibniz-Institute DSMZ). General protocol for treatment of cultured B16-
F10 cells: Cells were seeded one day before treatment to reach ~20 or 80% con-
fluence for 72 or 24 h treatments, respectively. The cell culture medium was
changed for medium containing 0.01% DMSO (D8418, Sigma Aldrich), 1 µM or
various doses of G007-LK (Mercachem or ChemRoyal), recombinant mouse
WNT3a (0.5 µg/mL, 1324-WN-010, R&D Systems), or a combination of G007-LK
(1 µM) and WNT3a.
Proliferation assays. 1000 cells/well were seeded in 96-well plates in at least 6
replicates for each treatment tested. The day after, cell culture medium was
changed to contain various doses of G007-LK or vehicle (DMSO, Sigma Aldrich)
and the plates were incubated in an IncuCyte (FLR30140, Essen BioScience) at 37 °
C for real-time monitoring of cell confluency. At experiment endpoint (80–100%
confluency after 5–7 days of cell growth), the cells were incubated for 1 h at 37 °C
with CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS,
Promega) according to the supplier’s recommendations. Abs490 was measured
spectrophotometrically (Wallac 1420 Victor2 Microplate Reader, Perkin Elmer)
and compared to Abs490 (t0) using the following formula to determine single well
values relative to the DMSO vehicle control: (sample A490− average A490 t0)×100/
(average A490 [for 0.01% DMSO controls] − average A490 t0).
Western blot analysis. Treated cells were washed in PBS and lysed in NP40 Cell
lysis buffer (Invitrogen) containing protease inhibitors. The nuclei were pelleted
and separated from the cytoplasmic/cell membrane supernatant fractions. RIPA
lysis buffer (89901, Thermo Fisher Scientific) containing phosphatase
(4906845001) and protease inhibitors (4693116001, both Sigma Aldrich) was
added to the nuclei followed by sonication (Bioruptor®Plus, Diagenode). Tumor
samples were prepared using TissueRuptor II (9002755, Qiagen), RIPA buffer and
sonication. Protein concentrations were measured using Pierce™ BCA Protein
Assay Kit (Pierce Biotechnology). The protein samples were separated by SDS
PAGE (Invitrogen) and immunoblotted (Immobilon-PSQ PVDF Membrane,
Millipore) using the following primary antibodies: Tankyrase-1/2 (TNKS1/2, H-
350, sc-8337, Santa Cruz Biotechnology), AXIN1 (C7B12, 3323, Cell Signaling
Technology), non-phospho (active) β-catenin (D13A1, 8814, Cell Signaling
Technology), β-catenin (610153,1:500, BD Biosciences), YAP (sc-101199, Santa
Cruz Biotechnology), TAZ (HPA007415, Sigma Aldrich), AMOT (sc-166924, Santa
Cruz Biotechnology), AMOTL1 (PA5-42267, Thermo Fisher Scientific), AMOTL2
(PA5-78770, Thermo Fisher Scientific), GSK3β (12456, Cell Signaling Technology),
phospho-GSK3β (Serine [Ser]9) (9323, Cell Signaling Technology). GAPDH (sc-
32233, Santa Cruz Biotechnology), β-tubulin III (T2200, Sigma Aldrich), actin
(A2066, Sigma Aldrich), and lamin B1 (ab16048, Abcam) were used as loading
controls. Primary antibodies were visualized with HRP-conjugated secondary
antibodies (mouse anti-rabbit IgG, sc-2357, Santa Cruz Biotechnology or donkey
anti-rabbit IgG, 711-035-152, Jackson ImmunoResearch Inc.) and enhanced with
chemiluminescent substrate (ECL™ Prime Western Blotting Detection Reagent,
RPN2236, GE Healthcare) and ChemiDoc™ Touch Imaging System (Bio-Rad).
Band quantifications (band of interest versus loading control) was performed using
Image Lab Sofware 5.2.1 (Bio-Rad).
RNA isolation and real-time qRT-PCR. Total RNA was isolated from cell lines
and tumor samples using GenEluteTM Mammalian Total RNA Miniprep Kit
(Sigma Aldrich). The RNA concentration was measured using Nanodrop 2000c
spectrophotometer (Thermo Scientific). cDNA was synthesized from the purified
RNA using SuperScript™ VILO cDNA Synthesis Kit (Invitrogen). Real-time qRT-
PCR (TaqMan®Gene Expression system, Applied Biosystems) was performed using
Viia7 (Applied Biosystems). The following probes were used (all from Applied
Biosystems): Axin2 (Mm00443610_m1), Tcf7 (Mm00493445_m1), Atf3
(Mm00476033_m1), Ccl4 (Mm00443111_m1), Amotl2 (Mm00502287_m1), Ctgf
(Mm01192933_g1), Cyr61 (Mm00487498_m1), AMOTL2 (Hs01048101_m1),
CTGF (Hs01026927_g1), CYR61 (Hs00998500_g1), and GAPDH
(Hs02758991_g1).
Luciferase reporter assays. The following plasmids were used: SuperTOP-
luciferase (WNT/β-catenin signaling pathway reporter with 7X TCF binding sites:
ST-Luc, gift from V. Korinek), SFF-Luc (negative control reporter with mutated
TCF binding sites: SuperFOPflash-luciferase, gift from V. Korinek), 8xGTIIC-
luciferase (Hippo and YAP signaling pathway reporter: 34615, Addgene, provided
by Dr. Stefano Piccolo54), β-catenin with deleted (del-β-catenin, gift from R.
Kemler) or point mutated (dominant active [DA] β-catenin [S33, 37, 41, 45 A], gift
from R. Kemler) N-terminal domain containing GSK3β phosphorylation sites and
Renilla luciferase (pRL-TK, Promega). On day 1, B16-F10 cells were seeded to
reach 50-60% confluency on day 2 for co-transfections (For reporter assays using
10-cm dishes: 16.5 µg luciferase reporter and 3 µg Renilla luciferase. For over-
expression assays using 6-well plates: 2.2 µg luciferase reporter, 0.1 µg del- β-
catenin, DA β-catenin or pCI-neo (empty vector, Promega) and 0.2 µg Renilla
luciferase for reporter assays) using FuGENE® HD (Promega). On day 3, the cells
were trypsinized and seeded in 96-well plates and treatment was added on day 4.
On day 5, the cells were lysed and the firefly and Renilla luciferase activities were
measured using Dual-Luciferase Reporter Assay (Promega) protocol and Glo-
Max®-Multi Detection System (Promega). XLfit (Idbs) was used to calculate the
half maximal inhibitory concentration (IC50) using the Langmuir Binding Isotherm
formula: fit= ((A+ (B × x)) + (((C-B)×(1-exp ((−1 × D)×x)))/D)), res= (y-fit).
CRISPR/Cas9-based knockout. RNA sequences targeting exon 4 of mouse
catenin (cadherin associated protein), beta 1 (Ctnnb1) were designed using the
web-based CHOPCHOP platform55: Ctnnb1_gRNA1: 5′- GATTAACTATCAGG
ATGACG-3′. The gRNA sequence was inserted into the pSPCas9(BB)-2A-GFP
vector (PX458, 48138, Addgene56) for transfection into tumor cells using poly-
ethylenimine (408727, Sigma Aldrich). After 24 h, GFP-expressing cells were
single-cell sorted (BD FACSAria II, BD Biosciences). Genomic DNA was isolated
from individual clones, the relevant gene fragment was amplified by PCR (Forward
primer: 5′-GTTCCCTGAGACGCTAGATGAG-3′. Reverse primer: 5′-ACATCA
CTGCTTACCTGGTCCT-3′.) and screened by Sanger sequencing for non-sense
mutations in Ctnnb1. Additional verification of gene knockout was performed by
immunofluorescence staining (primary antibody β-catenin [610153, 1:500, BD
Biosciences] and secondary antibody goat anti-mouse IgG Alexa 488 [A28175,
1:500, Thermo Fisher Scientific]) and western blot analysis (β-catenin, 1:500).
Immunofluorescence, SIM and confocal microscopy. Cells grown on coverslips
pre-coated with poly-L-lysine (sc-286689, Santa Cruz Biotechnology) were fixed in
4% paraformaldehyde (P6148, Sigma Aldrich) for 15 min at room temperature and
permeabilized with 0.1% Triton-X100/PBS (T8787, Sigma Aldrich, 15 min at room
temperature) followed by 1 hour (at room temperature for SIM images) or 24 h (at
4 °C for confocal images) incubations with primary and secondary (antibodies 1 h
at room temperature) diluted in PBS with 4% bovine serum albumin. Nuclear
counterstaining was performed with DAPI (D9542, Sigma Aldrich, 1 μg/mL, 5 min
at room temperature) and coverslips were mounted in ProLong Diamond Antifade
Mountant (Thermo Fisher Scientific). The following primary antibodies were used:
β-catenin (610153, 1:500, BD Biosciences), Tankyrase-1/2 (H-350, sc-8337, 1:50,
Santa Cruz Biotechnology [for SIM imaging]), Tankyrase-1/2 (E10, sc-365897,
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1:50, Santa Cruz Biotechnology [for confocal imaging]), YAP (sc-101199, 1:100,
Santa Cruz Biotechnology), AMOTL1 (PA5-42267, 1:50, Thermo Fisher Scientific)
and AMOTL2 (PA5-78770, 1:50, Thermo Fisher Scientific). Secondary antibodies
used (both from Thermo Fisher Scientific, 1:500): Anti-rabbit IgG Alexa488 (A-
21206) and anti-Mouse IgG Alexa594 (A-11005).
SIM images were acquired on a Zeiss Elyra PS1 microscope system using
standard filters sets and laser lines with a Plan-APOCHROMAT 63 × 1.4 NA oil
objective. SIM imaging was performed using 5 grid rotations with the 0.51 µm grid
for 20 Z planes with 0.184 nm spacing between planes. SIM images were
reconstructed with the following “Method” parameters in the ZEN black software
(MicroImaging, Carl Zeiss): Processing: Manual, Noise Filter: -5, SR Frequency
Weighting: 1, Baseline Cut, Sectioning: 100/83/83, Output: SR-SIM, PSF:
Theoretical. The SIM images are displayed as maximum intensity projections
rendered from all Z planes.
Confocal microscopy was performed on a Zeiss Meta 700 laser scanning
confocal microscope using standard filters sets and laser lines with a 63 × oil
immersion objective, images were acquired using Zen software (Zeiss). The
confocal images were analyzed using Fiji software57. Confocal images are displayed
as maximum intensity projections rendered from two Z-stacks at the nucleous
region with 0.56 µm spacing between stacks.
Tumor initiation, treatment and analysis of mouse melanoma in vivo. General
procedure: Subcutaneous B16-F10 and B16-F10Ctnnb1KO tumors (using Ctnnb1 KO
clone 1) were implanted (left flank, 0.2 × 106 tumor cells in 20 µl PBS) in female
B6N-Tyrc-Brd/BrdCrlCrl albino mice (C57BL/6N, Charles River) or female
RAGN12F; B6.129S6-Rag2tm1Fwa N12 mice (Rag2 [C57BL/6 background], Taconic
Biosciences). 1.0 × 106 Clone M-3(Z1) cells (ProQinase) in 100 µl were sub-
cutaneously implanted in female DBA/2 NCrl mice (DBA/2N, Charles River). All
mice were 3–8 weeks old at experiment startup. Randomization of mice to create
treatment groups with comparable tumor sizes was performed by random number
generation within individual blocks (MS-Excel 2016). Treatments used: (i) Control
(Purina 5001 diet, Research Diets Inc), (ii) G007-LK (250mg/kg in diet [ab libitum]
that delivers 43-53mg/kg/day, depending on measured food intake [3.2–4.4 g/
mouse/day] and body weight), (iii) anti-PD-1 (10mg/kg, intraperitoneally, i.p.
[RMP1-14, BE0146, batch 614616A2, Bio X Cell]), (iv) anti-PD-L1 (10mg/kg, i.p.
[10 F.9G2, BE0101, batch 6154598816S1, Bio X Cell]), (v) combinations of G007-LK
and anti-PD-1 or vi) G007-LK and anti-PD-L1. Previous analyses have documented
the pharmacokinetics of G007-LK in female mice using oral gavage delivery (t1/2=
2.6 hours and bioavailability= 76%) and in diet containing 250mg/kg G007-LK
(t1/2= 4.2 h)35,53. Compound delivery was monitored via food consumption. The
chow was weighed thrice weekly to calculate G007-LK delivery per animal and day.
Several animals had to be euthanized before experiment endpoint in all animal
experiments performed, primarily due to skin ulcerations in the tumor area seen in
all treatment groups, and less often due to anemia or excessive tumor size (tumor
diameter ≥ 2 cm). The experiment endpoints were defined to a minimum of 8 or
9 surviving animals in any given treatment group.
For experiments using B16-F10 Ctnnb1 knock-out cells in C57BL/6 N mice:
Intraperitoneal injections of anti-PD-1 were administered on day 11, 15, and 18.
For experiments using B16-F10 cells in C57BL/6 N mice: Intraperitoneal injections
of anti-PD-1 or anti-PD-L1 were administered on day 10, 13, 17 and every
3–4 days from day 21 until the end for the survival analysis. For experiments in
Rag2 mice or for Clone M-3(Z1) in DBA/2 N mice: Intraperitoneal injections of
anti-PD-1 were administered on day 8, 11, and 15. Primary tumors were measured
by a caliper (OMC Fontana) and tumor sizes calculated according to the formula
W2 × L/2 (L= length and W=width).
Assay for the efficacy of G007-LK-mediated inhibition of tankyrase and WNT/
β-catenin and YAP signaling pathways using B16-F10 cells in C57BL/6 N mice:
Mice with primary tumor volumes of 20-40 mm3 were randomized into two groups
(control or G007-LK for four nights, n= 8). Whole tumor protein extracts were
prepared by sonication in an ultrasound bath (Bioruptor® Plus, Diagenode) in
RIPA buffer (Thermo Fisher Scientific) containing phosphatase and protease
inhibitors (PhosStop, 4906837001 and cOmplete™ Protease Inhibitor Cocktail,
4693116001, both from Roche). Tumor tissues were homogenized using MagNA
Lyser Green Beads (Roche) and total mRNA isolated using GenEluteTM
Mammalian Total RNA Miniprep Kit (Sigma Aldrich).
Tumor growth assay using B16-F10 cells in C57BL/6 N mice: On day 10, 72
tumor-bearing animals (primary tumors reaching 20–100 mm3) were randomized
into six groups (n= 12), and treatments (i)–(vi) were administered to the mice. On
day 21, the experiment was terminated, and tumors from euthanized mice were
dissected, weighed and volumes re-measured with caliper. For 6 euthanized
animals from treatment groups (i), (ii), (iii), and (v): small intestinal was dissected,
formalin-fixed (10%), paraffin-embedded in a Swiss roll configuration and sections
were stained with H&E (115938 and 115935, Merck Millipore). 1, 2, 1, 4, 3, and 2
mice from treatment groups (i), (ii), (iii), (iv), and (v), respectively, were found
dead or euthanized for ethical reasons during the experiment due to anemia or skin
ulcerations in the tumor area.
Clone M-3(Z1) tumor growth assay: On day 8, 48 tumor-bearing animals (with
primary tumors reaching ~26 mm3) were randomized into 4 groups (n= 12) and
treatments (i), (ii), (iii), and (v) were administered to the respective mice. On day
18, the animals were euthanized and the tumors were dissected, weighed and
volumes re-measured with caliper. 4, 1, 3, and 1 mice from treatment groups (i),
(ii), (iii), and (v), respectively, were euthanized for ethical reasons during the
experiment due to skin ulcerations in the tumor area.
Survival assay using B16-F10 cells in C57BL/6 N mice: 60 animals with primary
tumors reaching 20–100 mm3 were randomized into 2 groups (n= 30, control or
G007-LK and anti-PD-1). The survival assay endpoint criterion was set to tumor
volume >1000 mm3. Eleven mice in the control group and 14 mice in the treatment
group were euthanized (for ethical reasons) or found dead due to anemia or skin
ulcerations in the tumor area before reaching the endpoint criterion. Tumors were
collected from surviving and treated animals at endpoint on day 38, and from
control animals euthanized on day 26. The tumors were dissected, fixed (10%
formalin), embedded in paraffin, sectioned and stained with H&E (115938 and
115935, Merck Millipore). For immunostaining, 2.5 µm sections were boiled for 20
min in 10 mM citrate buffer pH 6.0 and incubated with primary antibody anti-F4/
80 (2 µg/mL, clone CI: A3, ab6640, Abcam) diluted in PBS with 1.25% BSA
overnight at 4 °C, and then incubated with fluorescently labeled secondary
antibody (donkey anti-rat IgG Alexa Fluor 488, 5 µg/mL, A-21208, Molecular
Probes) for 60 min at 37 °C. Hoechst 33258 nuclear dye (0.5 µg/mL, Sigma Aldrich)
was added to the final washing solution. Pictures were captured using a Nikon
Eclipse model N i-U microscope (Nikon) equipped with Nikon Plan-Fluor
objective lenses and an Infinity 2 digital camera (Lumenera Corporation).
Tumor growth assay using B16-F10 Ctnnb1 knock-out cells in C57BL/6 N mice:
On day 11, 48 tumor-bearing animals (primary tumors reaching 20–100 mm3)
were randomized into 4 groups (n= 12), each treated with (i), (ii), (iii), or (v). On
day 25, mice were euthanized, and the tumors were dissected, weighed and volumes
re-measured with caliper. Three mice from treatment group (i) and two mice from
treatment groups (ii), (iii) and (v) were euthanized for ethical reasons before
experiment termination, due to skin ulcerations in the tumor area or excessive
tumor size. For immunostaining, 2.5 µm frozen sections were incubated with
primary antibody anti-CD8 (5 µg/mL, clone 4SM15, eBioscience) diluted in PBS
with 1.25% BSA for 60 min at 37 °C and then incubated with secondary antibody
(donkey anti-rat IgG Alexa Fluor 488, 5 µg/mL, Thermo Fisher Scientific) for 60
min at 37 °C. Hoechst 33258 nuclear dye (0.5 µg/mL, Sigma Aldrich) was added to
the final washing solution. For semi-quantitative analysis, the three areas (high
power fields) from each tumor section that contained the highest number of CD8+
T cells were selected and the number of T cells were counted in each area. The
mean value of the three scored areas in each tumor was calculated and next used in
statistical analyses.
Tumor growth assay using B16-F10 cells in B6.129S6-Rag2tm1Fwa N12 mice
(Rag2−/−)40 mice: On day 8, 24 tumor-bearing animals (with primary tumors
reaching 18-61mm3) were randomized into two groups (n= 12), and treatments (i)
and (v) were administered to the respective mice. On day 20, the animals were
euthanized. One mouse from treatment group (i) and two mice from treatment
group (v) were euthanized for ethical reasons before experiment termination, due
to skin ulcerations in the tumor area or excessive tumor size.
Tumor growth assay using B16-F10 cells, CD8α depletion and IFNγ
neutralization in C57BL/6 N mice: On day 7, 120 tumor-bearing animals (primary
tumors reaching 14-45 mm3) were randomized into eight groups (n= 15): (i)
Control diet, (ii) anti-IgG1 (BE0088, Bio X Cell, isotype control for IFNγ), (iii)
anti-IgG2 (BE0090, Bio X Cell), isotype control for anti-CD8α), (iv) anti-CD8α
(BE0061, Bio X Cell), (v) anti-IFNγ (BE0055, Bio X Cell), (vi) anti-PD-1/G007-LK,
(vii) anti-PD-1/G007-LK/anti-CD8α, and (viii) anti-PD-1/G007-LK/anti-IFNγ.
200 µg/mouse of isotype control, depleting and neutralizing antibodies were
delivered intraperitoneally on day 7, 10, 13, 17, and 20. Anti-PD-1/G007-LK
treatment was initiated on day 10. On day 21, the experiment was terminated, and
tumors from euthanized mice were dissected, weighed and volumes re-measured
with caliper. 4, 3, 5, 5, 6, 5, 6, and 6 mice from treatment groups (i), (ii), (iii), (iv),
(v), (vi), (vii), and (viii), respectively, were found dead or euthanized for ethical
reasons during the experiment due to anemia or skin ulcerations in the tumor area.
At experiment end, spleens from two animals in group (i), (iii), (iv), and (vii) were
dissected and single cells were collected by squeezing the spleen through a cell
strainer. Erythrocytes were removed with the Red Blood Cell Lysis Solution
(Miltenyi Biotec) and 5 × 105 cells/well were dispensed into 96-well plates. The cells
were washed with PBS and stained for living cells for 30 min (FVS780, BD
Biosciences). After washing and centrifugation (400 × g), the samples were
incubated with 50 µl/well of Fc block (anti-mouse CD16/CD32, 1:50, 14-0161-85,
clone 93, eBioscience) for 15 min in FACS buffer (PBS with 2% FCS and 0.2%
EDTA, 03690, Sigma Aldrich). Thereafter, 50 µl of the following 2X concentrated
antibody master mix was added to each well and incubated for 30 min in the dark:
BD Horizon™ BUV395 Rat Anti-Mouse CD45 (565967), BV786 Hamster Anti-
Mouse CD3e (564379) and BD Horizon™ APC-R700 Rat Anti-Mouse CD8a
(564983) (all from BD Biosciences). The cells were fixed and analyzed by flow
cytometry using a LSR Fortessa (BD Biosciences) with the gating shown in
Supplementary Fig. 16b.
All animal experiment described in this section were performed by ProQinase
GmbH, following approval by local animal experiment authorities (Freiburg,
Germany) and in compliance with FELASA guidelines and recommendations.
Multiplex and ELISA immunoassay. Subcutaneous B16-F10 tumors were
implanted (left flank, 0.2 × 106 B16-F10 tumor cells suspended in 200 µl [2:1] PBS:
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matrigel mixture) in 6–8 weeks old female C57BL/6 mice (Taconic). On day 6,
animals were distributed into four groups and treatments (i) (n= 3), (ii) (n= 6),
(iii) (n= 5), and (v) (n= 8) were administered to the mice (see paragraph
describing tumor initiation, treatment and analysis of mouse melanoma in vivo).
Intraperitoneal injections of anti-PD-1 were administered on day 6, 9, and 13. On
day 14, the animals were euthanized and the matrigel-implanted tumors were
dissected, treated with 1 mg/mL type IV collagenase and 0.3 mg/mL DNase I (both
from Sigma Aldrich) in RPMI and incubated for 45 min at 37 °C. The samples were
next centrifuged (1500 × g) and the conditioned supernatants collected39. The
animal experiment was approved by local animal experiment authorities (Nor-
wegian Food Safety Authority, Norway) and in compliance with FELASA guide-
lines and recommendations. Bio-Plex Pro Mouse Chemokine Panel 33-plex
(12002231, Bio-Rad) was used to screen the in vivo tumor conditioned super-
natants for cytokine and chemokine expression according to the manufacturer’s
protocol. A Bio-Plex handheld magnetic washer (Bio-Rad) was used for the wash
steps, and a Luminex-100 instrument with Bio-Plex Manager 4.1 software (Bio-
Rad) was used for analysis. Cell supernatants from treated cells and conditioned
B16-F10 tumor supernatants (see description for multiplex immunoassay) were
assayed using Mouse CCL4/MIP-1 β Quantikine ELISA Kit (MMB00, R&D Sys-
tems) according to the manufacturer's protocol.
Tumor flow cytometry analysis. Primary tumor from treatment groups (i), (ii),
(iii), and (v) was collected and processed for flow cytometry analysis to determine
the presence of subpopulations of T cells and myeloid-derived suppressor cells
(carried out by ProQinase58,59). For analysis of T cells and myeloid-derived sup-
pressor cells, animals were treated for 7–17 days to obtain similarly distributed
primary tumor volumes ranging from 80–240 mm3 (Supplementary Fig. 17a). The
animal experiment was performed by ProQinase GmbH, following approval by
local animal experiment authorities (Freiburg, Germany) and in compliance with
FELASA guidelines and recommendations. Tumors were disrupted using gentle-
MACS Tubes (Miltenyi Biotec) containing the enzyme mix of the Tumor Dis-
sociation Kit according to the manufacturer’s instructions (Miltenyi Biotech).
Erythrocytes were removed with the Red Blood Cell Lysis Solution (Miltenyi
Biotech). Single-cell suspensions were counted, and up to 3 × 106 cells/well were
dispensed into 96-well plates. The single cells were washed with PBS and stained
for living cells (eBioscienceTM Fixable Viability Dye eFluor™ 455UV [65-0868-14,
eBioscience]). After washing and centrifugation (400 × g), the samples were incu-
bated with 50 µl/well of Fc block (anti-mouse CD16/CD32, 1:50, 14-0161-85, clone
93, eBioscience) for 30 min in FACS buffer (PBS with 2% FCS and 0.2% EDTA,
03690, Sigma Aldrich). Thereafter, 50 µl of the following 2X concentrated antibody
master mixes were added to each well and incubated for 30 minutes in the dark.
For T cells, the following antibodies against murine targets were used: CD45
(CD45-PacBlue [30-F11], 48-0451-82, eBioscience), CD3 (CD3-Violet 605 [17A2],
BioLegend), CD4 (CD4-APC-Cy7 [GK1.5], 47-0041-82, eBioscience), CD8a (CD8-
PerCP [53-6.7], eBioscience), CD25 (CD25-APC [PC61.5], 17-0251-82,
eBioscience) and CD44 (CD44-FITC [IM7], 11-0441-82, eBioscience). For myeloid
cells, the following antibodies against murine targets were used: CD45 (CD45-
PacBlue [30-F11], 48-0451-82, eBioscience), CD11b (CD11b-FITC [M1/70], 11-
0112-82, eBioscience), CD11c (CD11c-APC-Cy7 [N418], 47-0114-80, eBioscience),
lymphocyte antigen 6 complex, locus G (Ly6G)(Ly6G-APC [RB6-8C5], 17-5931-
81, eBioscience), lymphocyte antigen 6 complex, locus C1 (Ly6C)(Ly6C-PE
[HK1.4], 12-5932-82, eBioscience) and CD103 (CD103 [Integrin alpha E], PerCP-
Cy5.5 [2E7], 121415, BioLegend). The cells were washed and fixed. Cells stained
with the T cell panel markers were prepared for intracellular staining by adding 50
µl fixation/permeabilization (1:3) buffer (00-5523-00, eBioscience) for 30 min.
Thereafter, 100 µl 1X permeabilization buffer (00-5523-00, eBioscience) was added
and the cells were centrifuged at 400 × g. The cell pellet was resuspended in 1X
permeabilization buffer containing anti- forkhead box P3 (FoxP3) antibody
(FoxP3-PE [FJK-16s], 12-5773-82, eBioscience) and incubated for 30 minutes in
the dark. After washing twice with permeabilization buffer, the cells were washed
with FACS buffer and kept at 4 °C in the dark until analysis. The samples were
analyzed by flow cytometry using an LSR Fortessa (BD Biosciences) and the gating
strategy is shown in Supplementary Fig. 18a, b.
In vitro T-cell assays. Eight weeks old, female and wild-type C57BL/6 and C57BL/
6-Tg(TcraTcrb)1100Mjb/J (OT-I) mice, harboring major histocompatibility com-
plex (MHC) class I (H2-Kb)-restricted and ovalbumin-specific CD8+ T cells, were
obtained from Jackson Laboratories. For the T cell proliferation and cytokine
release-assays, spleen and lymph nodes were harvested from OT-1 mice and CD8+
T cells were sorted by using the Miltenyi CD8a+ T Cell Isolation Kit (130-104-075).
Splenocytes from wild-type C57BL/6 mice were irradiated (25 Gy) and used as
antigen-presenting cells. Antigen-presenting cells and CD8+ T cells were mixed at
a 4:1 ratio with 100,000 APCs and 25,000 T cells per well in 96-well plates. For
activation of OT-1 CD8+ T cells, 4 µg/ml of synthetic SIINFEKL peptide (Ana-
Spec) was added. For polyclonal T cell activation, Concanavalin A (5 µg/ml, Sigma
Aldrich) or immobilized CD3 (0.5 µg/ml)/CD28 (5 µg/ml) antibodies (clones 145-
2c11 and 37.51, BioXCell) were used. To evaluate the effect of G007-LK on T cell
proliferation and cytokine production, 1 µM G007-LK or vehicle control (0.01%
DMSO) was added to all conditions. For proliferation assays, 3H-Thymidine
(Montebello Diagnostics, Oslo, Norway) was added after 48 or 72 h of treatment.
Cells were harvested after 24 additional hours and radiolabeling was counted with a
MicroBeta plate reader. Supernatant was harvested from the plates after 72 h of
treatment. IL2 and IFNγ quantitation in culture supernatants was determined
using ELISA Max Deluxe kits (431004 and 430804, Biolegend). For flow cytometric
analysis of surface markers on APC/ SIINFEKL or ConA-activated CD8+ T cells,
the cells were pooled from 8–12 wells from the setup described previously and the
following antibodies were used: Anti-CD62L (1705-09 L, Southern biotech), anti-
CD69 (1715-02, Southern biotech), anti-CD8a (553036, BD Biosciences), anti-
CD25 (17-0251-82, eBioscience), anti-CD44 (103049, Biolegend), and anti-CD3e
(35-0031, TONBO Biosciences). For intracellular staining, the cells were incubated
for 4 h in protein-transport inhibitor before permeabilization and fixation,
according to the manufactures’ protocol (Fix/Perm kit with Golgistop 554715, BD
Biosciences) and then stained with anti-granzyme B (12-8898-82, eBioscience). All
antibodies were used at a working concentration of 2 µg/ml. The samples were
analyzed using the Attune NxT flow cytometer (Thermo Fisher Scientific) and
Flow Jo software (BD Biosciences).
RNA sequencing. The following samples were used for RNA sequencing experi-
ments and RNA was isolated using GenEluteTM Mammalian Total RNA Miniprep
Kit (Sigma Aldrich): Three biological replicates of cultured B16-F10 cells, treated
with DMSO (0.01%), G007-LK (1 µM), WNT3a (0.5 µg/mL) or G007-LK and
WNT3a for 24 h. And in addition, three pooled technical replicates from a panel of
18 human melanoma cell lines treated with DMSO (0.01%) or G007-LK (1 µM) for
24 hours: The cell lines SK-MEL-28, MeWo, and A-375 were obtained from the
American Type Culture Collection (ATCC). WM35, WM115, WM1341B,
WM1366, WM983B, WM451Lu, WM239A, WM266.4, WM852, WM1382, WM9,
WM793B were obtained from the Wistar Institute. LOX-IMVI, FEMX-I and
FEMX-V were established at the Norwegian Radium Hospital (Oslo, Norway). Cell
line authentication was performed by short tandem repeat profiling and subsequent
analysis at the Norwegian Radium Hospital. RNA sequencing (TruSeq Stranded
mRNA kit for library prep and NextSeq500 v2 chemistry used for sequencing, both
Illumina Inc.) was performed at the Genomics Core Facility Oslo (Oslo University
Hospital, Norway).
DNA sequencing. Kinome targeted re-sequencing of the 18 human melanoma cell
lines was performed using the SureSelect Human Kinome kit (Agilent Technolo-
gies), with capture probes targeting 3.2 Mb of the human genome, including exons
and untranslated regions (UTRs) of all known kinases and selected cancer‐related
genes (to a total of 612 genes). Library construction and in solution capturing was
performed following Agilent’s SureSelectXT library construction kit and SureSelect
Target enrichment protocol, respectively. Sequencing was performed on an Illu-
mina HiSeq2500 using the TruSeq SBS Kit v5 generating paired‐end reads of 75 bp
in length. Base calling, de-multiplexing and quality filtering was performed using
Illumina’s software packages SCS2.8/RTA1.8 and Off‐line Basecaller‐v1.8.
Bioinformatics. Transcripts were quantified with kallisto (v0.44)60 using ensembl
transcriptome release 91 for human (GRCh38) and release 92 for mouse
(GRCm38)61. Ensemble BioMart was used to map human orthologs in mouse60.
Differentially expressed genes (DEGs) were identified with sleuth (v0.29)62, limma
(3.34.9)63 (did not result in any comparisons with adjusted P values < 0.05) and
DESeq264 in the R programming environment (The R Project for Statistical
Computing). The R-package NMF (0.23.6)65 was used to make hierarchical clusters
with TPM values as input. For detection of probable driver mutations, the RNAseq
data was aligned with HISAT2 (v2.1.0)66 before VarDict (v1.2)67 restricted to SNVs
reported more than once in COSMIC (v82)68 was applied. Due to the variable
coverage in RNAseq data, additional SNVs found in an external unpublished gene
panel sequencing experiment for the same cell lines, were included. Variants found
in both datasets were annotated using ANNOVAR (2017-07-17)69. The data
analysis was performed by the Bioinformatics Core Facility (Oslo University
Hospital, Norway). DEGs analysis data, including log2-fold change and adjusted p-
values, were uploaded into Ingenuity Pathway Analysis (IPA) version 01-10
(Qiagen). The DEGs analysis data were analyzed using the core analysis function
with the Ingenuity Knowledge Base (genes only) reference set and direct rela-
tionships, with no filters set for node types, data sources, confidence, species,
tissues, and cell lines and mutations. For the IPA core analyses, the log2-fold and or
adjusted p-value cutoffs are specified in the figure legends.
Statistics and reproducibility. No sample size calculation was performed. Sample
sizes for both in vivo and in vitro experiments were determined based on experiment
experience, pilots and preliminary experiments as well as what was reported in the
literature. Samples sizes for each experiment and numbers of independent repeats are
indicated in figure legends. All in vivo experiments included contain ≥8 independent
biological replicates, except for Fig. 4a, b (≥3) and Fig. 5e (≥3). For all in vitro assays,
all attempts at replication were successful through repeated experiments (two or more
replications). Sigma Plot® 12.5 (Systat Software Inc.) was used to perform statistical
tests: Student’s t-test for comparisons with homogeneous variances (Shapiro-Wilk
test, P > 0.05) and Mann-Whitney rank sum tests for comparisons where the nor-
mality assumption was violated (Shapiro-Wilk test, P < 0.05). GrapPad Prism 7 was
used for Kaplan-Meyer estimations and statistical analysis. Single outlier detections
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were identified by Dixon’s and/or Grubb’s tests (threshold, P < 0.05) using Con-
trolFreak (Contchart software).
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA sequencing data for this study are available from ArrayExpress with accession
numbers E-MTAB-8438 (human cell lines) and E-MTAB-8101 (B16-F10 mouse cell
line). For the mouse experiment, the data are deposited both as raw fastq files and
processed as RNA abundance counts. For the human RNA experiment only abundance
counts are deposited. Somatic mutations from DNA sequencing are available at https://
github.com/ous-uio-bioinfo-core/waaler-et-al-2020; 10.5281/zenodo.3703045. Fastq files
for the human sequencing experiments and additional data generated and analyzed in
this study are available from the corresponding author upon request. The source data
underlying plots shown in main figures are provided in Supplementary Data 1.
Additional data generated and analyzed in this study are available from the
corresponding author upon request.
Code availability
Custom scripts used to process and analyze the sequencing data and to make most of the
related figures and tables are available at https://doi.org/10.5281/zenodo.3703045.
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